19 May 2022 
EMA/CHMP/266096/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Nexpovio 
selinexor 
On 19 May 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Nexpovio. 
The marketing authorisation holder for this medicinal product is Karyopharm Europe GmbH. 
The CHMP adopted a new indication for multiple myeloma. The full indications for Nexpovio will therefore 
be as follows:2 
Nexpovio is indicated: 
• 
• 
in combination with bortezomib and dexamethasone for the treatment of adult 
patients with multiple myeloma who have received at least one prior therapy. 
in combination with dexamethasone for the treatment of multiple myeloma in adult patients 
who have received at least four prior therapies and whose disease is refractory to at least 
two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal 
antibody, and who have demonstrated disease progression on the last therapy. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
